Review

soluble dimeric ace2 (Addgene inc)

Addgene inc is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Addgene inc soluble dimeric ace2

Binding properties of novel trispecific antibodies. (A) Recombinant human <t>ACE2</t> was immobilized on HIS1K sensors, followed by the addition of a mixture containing the indicated antibodies and SARS‐CoV‐2 WT spike trimer. As a positive control, the antibody was instead by PBST buffer, and then was loaded onto the human ACE2 immobilized biosensor (gray). (B) The XBB trimer was captured onto the HIS1K biosensors. Then, PW5‐5, PW5‐535, and PW5‐570 were sequentially used to saturate the trimer binding sites, and the association of Tri‐1 or Tri‐2 was subsequently measured. (C) The XBB trimer was initially captured onto the HIS1K biosensors, following the indicated prototype antibody (PW5‐5, PW5‐535, or PW5‐570) was injected onto the RBD‐connected biosensors, which have already saturated with Tri‐1 (left) or Tri‐2 (right). (D and E) The XBB.1.16 RBD was captured onto the HIS1K biosensors at 40, 200, and 1000 ng/mL for 300 s, respectively. Summary of the data (D) or scatter plot (E) of the affinities ( K D ), association ( K on ), and dissociation ( K off ) of Tri‐1‐ and structural‐related mAbs and bsAbs to indicated concentrations RBD.

Soluble Dimeric Ace2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/soluble dimeric ace2/product/Addgene inc
Average 91 stars, based on 1 article reviews

soluble dimeric ace2 - by Bioz Stars, 2026-05

91/100 stars

Images

1) Product Images from "Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses"

Article Title: Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses

Journal: MedComm

doi: 10.1002/mco2.70191

Binding properties of novel trispecific antibodies. (A) Recombinant human ACE2 was immobilized on HIS1K sensors, followed by the addition of a mixture containing the indicated antibodies and SARS‐CoV‐2 WT spike trimer. As a positive control, the antibody was instead by PBST buffer, and then was loaded onto the human ACE2 immobilized biosensor (gray). (B) The XBB trimer was captured onto the HIS1K biosensors. Then, PW5‐5, PW5‐535, and PW5‐570 were sequentially used to saturate the trimer binding sites, and the association of Tri‐1 or Tri‐2 was subsequently measured. (C) The XBB trimer was initially captured onto the HIS1K biosensors, following the indicated prototype antibody (PW5‐5, PW5‐535, or PW5‐570) was injected onto the RBD‐connected biosensors, which have already saturated with Tri‐1 (left) or Tri‐2 (right). (D and E) The XBB.1.16 RBD was captured onto the HIS1K biosensors at 40, 200, and 1000 ng/mL for 300 s, respectively. Summary of the data (D) or scatter plot (E) of the affinities ( K D ), association ( K on ), and dissociation ( K off ) of Tri‐1‐ and structural‐related mAbs and bsAbs to indicated concentrations RBD.

Figure Legend Snippet: Binding properties of novel trispecific antibodies. (A) Recombinant human ACE2 was immobilized on HIS1K sensors, followed by the addition of a mixture containing the indicated antibodies and SARS‐CoV‐2 WT spike trimer. As a positive control, the antibody was instead by PBST buffer, and then was loaded onto the human ACE2 immobilized biosensor (gray). (B) The XBB trimer was captured onto the HIS1K biosensors. Then, PW5‐5, PW5‐535, and PW5‐570 were sequentially used to saturate the trimer binding sites, and the association of Tri‐1 or Tri‐2 was subsequently measured. (C) The XBB trimer was initially captured onto the HIS1K biosensors, following the indicated prototype antibody (PW5‐5, PW5‐535, or PW5‐570) was injected onto the RBD‐connected biosensors, which have already saturated with Tri‐1 (left) or Tri‐2 (right). (D and E) The XBB.1.16 RBD was captured onto the HIS1K biosensors at 40, 200, and 1000 ng/mL for 300 s, respectively. Summary of the data (D) or scatter plot (E) of the affinities ( K D ), association ( K on ), and dissociation ( K off ) of Tri‐1‐ and structural‐related mAbs and bsAbs to indicated concentrations RBD.

Techniques Used: Binding Assay, Recombinant, Positive Control, Injection

Image Search Results

Journal: MedComm

Article Title: Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses

doi: 10.1002/mco2.70191

Figure Lengend Snippet: Binding properties of novel trispecific antibodies. (A) Recombinant human ACE2 was immobilized on HIS1K sensors, followed by the addition of a mixture containing the indicated antibodies and SARS‐CoV‐2 WT spike trimer. As a positive control, the antibody was instead by PBST buffer, and then was loaded onto the human ACE2 immobilized biosensor (gray). (B) The XBB trimer was captured onto the HIS1K biosensors. Then, PW5‐5, PW5‐535, and PW5‐570 were sequentially used to saturate the trimer binding sites, and the association of Tri‐1 or Tri‐2 was subsequently measured. (C) The XBB trimer was initially captured onto the HIS1K biosensors, following the indicated prototype antibody (PW5‐5, PW5‐535, or PW5‐570) was injected onto the RBD‐connected biosensors, which have already saturated with Tri‐1 (left) or Tri‐2 (right). (D and E) The XBB.1.16 RBD was captured onto the HIS1K biosensors at 40, 200, and 1000 ng/mL for 300 s, respectively. Summary of the data (D) or scatter plot (E) of the affinities ( K D ), association ( K on ), and dissociation ( K off ) of Tri‐1‐ and structural‐related mAbs and bsAbs to indicated concentrations RBD.

Article Snippet: The mammalian expression plasmid encoding recombinant soluble dimeric ACE2 was obtained from Addgene.

Techniques: Binding Assay, Recombinant, Positive Control, Injection

Neutralization of SARS-CoV-2 variants and SARS-CoV by “Knob-into-Hole” bsAbs . (A) Schematic diagrams illustrating the structure of “Knob-into-Hole” bsAbs, with one arm targeting the receptor and the other targeting the SARS-CoV-2 S trimer. The anti-receptor and anti-viral arms are depicted in blue and orange, respectively. (B) Neutralization IC 50 titres of the bsAbs against SARS-CoV-2 variants (WT, BA.2, BA.5, XBB.1.5) and SARS-CoV. (C) Comparative analysis of IC 50 values for different bsAb designs. H11B11_* and *_H11B11 denote the positioning of the H11B11 arm in the “Knob” and “Hole-Cross’ configurations, respectively. (D) Binding activities of H11B11_Brii-196 and Brii-196_H11B11 to the SARS-CoV-2 S trimer and sACE2 protein. (E) Neutralization of representative SARS-CoV-2 WT and BA.5 pseudoviruses by H11B11_Brii-196, alongside parental and single-arm antibodies. (F) Neutralization activity of HP6H8_Brii-196 and its parental antibodies against various SARS-CoV-2 variants and SARS-CoV.

Journal: Emerging Microbes & Infections

Article Title: Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes

doi: 10.1080/22221751.2024.2404166

Figure Lengend Snippet: Neutralization of SARS-CoV-2 variants and SARS-CoV by “Knob-into-Hole” bsAbs . (A) Schematic diagrams illustrating the structure of “Knob-into-Hole” bsAbs, with one arm targeting the receptor and the other targeting the SARS-CoV-2 S trimer. The anti-receptor and anti-viral arms are depicted in blue and orange, respectively. (B) Neutralization IC 50 titres of the bsAbs against SARS-CoV-2 variants (WT, BA.2, BA.5, XBB.1.5) and SARS-CoV. (C) Comparative analysis of IC 50 values for different bsAb designs. H11B11_* and *_H11B11 denote the positioning of the H11B11 arm in the “Knob” and “Hole-Cross’ configurations, respectively. (D) Binding activities of H11B11_Brii-196 and Brii-196_H11B11 to the SARS-CoV-2 S trimer and sACE2 protein. (E) Neutralization of representative SARS-CoV-2 WT and BA.5 pseudoviruses by H11B11_Brii-196, alongside parental and single-arm antibodies. (F) Neutralization activity of HP6H8_Brii-196 and its parental antibodies against various SARS-CoV-2 variants and SARS-CoV.

Article Snippet: The mammalian expression plasmid for dimeric soluble ACE2 was purchased from Addgene (#154101).

Techniques: Neutralization, Binding Assay, Activity Assay

Neutralization of SARS-CoV-2 variants, SARS-CoV, and MERS-CoV by “Knob-into-Hole” bsAbs . (A) SEC analysis of the “Knob-into-Hole” bsAbs – H11B11_M336 and M336_H11B11, demonstrating the purity and monodispersity of these antibody constructs. (B) Binding activities of H11B11_M336 and M336_H11B11 to the MERS-CoV S trimer and sACE2 protein. (C) Comparative neutralization by H11B11_M336, M336_H11B11 and the mixture of H11B11 and M336, against SARS-CoV-2 variants (WT, BA.2, BA.5, XBB.1.5), SARS-CoV, and MERS-CoV. (D) Neutralization of representative SARS-CoV-2 WT, BA.5, and MERS-CoV pseudoviruses by H11B11_M336, alongside parental and single-arm antibodies.

Journal: Emerging Microbes & Infections

Article Title: Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes

doi: 10.1080/22221751.2024.2404166

Figure Lengend Snippet: Neutralization of SARS-CoV-2 variants, SARS-CoV, and MERS-CoV by “Knob-into-Hole” bsAbs . (A) SEC analysis of the “Knob-into-Hole” bsAbs – H11B11_M336 and M336_H11B11, demonstrating the purity and monodispersity of these antibody constructs. (B) Binding activities of H11B11_M336 and M336_H11B11 to the MERS-CoV S trimer and sACE2 protein. (C) Comparative neutralization by H11B11_M336, M336_H11B11 and the mixture of H11B11 and M336, against SARS-CoV-2 variants (WT, BA.2, BA.5, XBB.1.5), SARS-CoV, and MERS-CoV. (D) Neutralization of representative SARS-CoV-2 WT, BA.5, and MERS-CoV pseudoviruses by H11B11_M336, alongside parental and single-arm antibodies.

Article Snippet: The mammalian expression plasmid for dimeric soluble ACE2 was purchased from Addgene (#154101).

Techniques: Neutralization, Construct, Binding Assay

Journal: Emerging Microbes & Infections

Article Title: Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes

doi: 10.1080/22221751.2024.2404166

Figure Lengend Snippet: Neutralization of SARS-CoV-2 variants, SARS-CoV, and MERS-CoV by “IgG-scFv” bsAbs . (A) Schematic diagrams of “IgG-scFv” bsAbs structures, showcasing anti-viral antibodies (Brii-196 or m336) linked in the scFv format to the C-terminus of the anti-ACE2 H11B11 IgG, or vice versa. (B) Binding activities of the four “IgG-scFv” bsAbs to the SARS-CoV-2/MERS-CoV S trimer and sACE2 protein. (C) Neutralization of the four “IgG-scFv” bsAbs against the representative SARS-CoV-2 (WT, BA.2, BA.5, XBB.1.5), SARS-CoV and MERS-CoV pseudoviruses. (D) Comprehensive neutralization profile of the four “IgG-scFv” bsAbs and three parental antibodies against an expanded panel of 24 pseudoviruses, including additional SARS-CoV-2 variants and animal coronaviruses. (E) Comparative analysis of the neutralization efficacy of H11B11_m336 in the “IgG-scFv” format versus the “Knob-into-Hole” format.

Article Snippet: The mammalian expression plasmid for dimeric soluble ACE2 was purchased from Addgene (#154101).

Techniques: Neutralization, Binding Assay

Review

Structured Review

Images

1) Product Images from "Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses"

Similar Products

Image Search Results